Regulations.gov document
ATTACHMENT 2 - Empagliflozin and Linagliptin Capsules re Request that the FDA declare that…
Supporting & Related Material · FDA-2017-P-2674 · posted Apr 28, 2017
Key facts
| Document ID | FDA-2017-P-2674-0004 |
|---|---|
| Title | ATTACHMENT 2 - Empagliflozin and Linagliptin Capsules re Request that the FDA declare that Empagliflozin and Linagliptin Capsules 10 mg; 5 mg , 25 mg: 5 mg are suitable for submission as an Abbreviated New Drug Application (ANDA) |
| Document type | Supporting & Related Material |
| Subtype | Background Material |
| Agency | FDA |
| Docket | FDA-2017-P-2674 |
| Posted | Apr 28, 2017 |
At a glance
- None Pages
- None Public comments on this docket
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Regulations.gov documents
Regulations.gov holds the rulemaking and other documents federal agencies post for public comment. Only agency documents are published here; public submissions are not.
Source: Regulations.gov (U.S. General Services Administration eRulemaking Program) · Source date: